SCHEMBL988652

SCHEMBL988652

CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC3(CCCCC3)O[C@@H]2[C@@H]1OC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CA2 P00918 4/20 0.33
▸ APOBEC3A P31941 1/20 0.32
▸ CTDSP1 Q9GZU7 1/20 0.32
▸ APOBEC3G Q9HC16 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ CA9 Q16790 2/20 0.30
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19479799 1.00 POLB (0.33) POLBGAAMAPK1NPSR1CA2
SCHEMBL19479801 1.00 POLB (0.33) POLBGAAMAPK1NPSR1CA2
SCHEMBL9225694 0.85 POLB (0.30) POLBGAAMAPK1NPSR1CA2
SCHEMBL18408761 0.80 POLB (0.39) POLBGAAMAPK1NPSR1ALDH1A1
SCHEMBL21549585 0.77 CA2 (0.36) POLBGAAMAPK1NPSR1CA2
SCHEMBL20402067 0.77 CA2 (0.33) CA2
SCHEMBL21757659 0.74 THRB (0.34) POLBGAAMAPK1NPSR1CA2
SCHEMBL21231939 0.74 THRB (0.34) POLBGAAMAPK1NPSR1CA2
SCHEMBL463763 0.73 ALDH1A1 (0.32) ALDH1A1
SCHEMBL6380233 0.72 CA2 (0.31) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338849-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2021-11-04 — — US disclosed
EP-3231804-B1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2021-03-03 — — EP disclosed
US-10857247-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders THE GENERAL HOSPITAL CORPORATION (US) 2020-12-08 — — US disclosed
EP-3231804-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS The General Hospital Corporation (US) 2017-10-18 — — EP disclosed
EP-2268647-B1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2017-01-25 — — EP disclosed
US-9005578-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders FLUOROPHARMA, INC. (US) 2015-04-14 — — US disclosed
US-20150098903-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders THE GENERAL HOSPITAL CORPORATION 2015-04-09 — — US disclosed
US-20130315827-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders FLUOROPHARMA, INC. (US) 2013-11-28 — — US disclosed
US-8450466-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders THE GENERAL HOSPTIAL CORPORATION (US) 2013-05-28 — — US disclosed
US-20110060138-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders THE GENERAL HOSPITAL CORPORATION 2011-03-10 — — US disclosed
EP-2268647-A2 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS The General Hospital Corporation (US) 2011-01-05 — — EP disclosed
WO-2009117728-A2 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338849-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS APP, PSEN1, PSEN2 POLB 3800/4885GAA 29/4885MAPK1 4002/4885
US-10857247-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders APP, PSEN1, PSEN2 POLB 3800/4885GAA 29/4885MAPK1 4002/4885
US-20130315827-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 POLB 3800/4885GAA 29/4885MAPK1 4002/4885
US-20150098903-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 POLB 3800/4885GAA 29/4885MAPK1 4002/4885
US-20110060138-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 POLB 3800/4885GAA 29/4885MAPK1 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback